Vaccines and Disease-Modifying Antirheumatic Drugs Practical Implications for the Rheumatologist

被引：45

作者：

Friedman, Marcia A. ^{[1
]}

Winthrop, Kevin L. ^{[2
]}

机构：

[1] Oregon Hlth & Sci Univ, Dept Rheumatol, Mail Code OP09,3181 Southwest Sam Jackson Pk Rd, Portland, OR 97239 USA

[2] Oregon Hlth & Sci Univ, Dept Infect Dis, 840 SW Gaines Rd, Portland, OR 97239 USA

来源：

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA | 2017年 / 43卷 / 01期

关键词：

Vaccine; Rheumatoid arthritis; DMARD; Biologic; Anti-TNF; Rituximab; Immunogenicity; Efficacy; NECROSIS-FACTOR-ALPHA; B-VIRUS REACTIVATION; PNEUMOCOCCAL POLYSACCHARIDE VACCINATION; ADVISORY-COMMITTEE; ANTIBODY-RESPONSE; HERPES-ZOSTER; IMMUNIZATION PRACTICES; IMMUNE-RESPONSE; ARTHRITIS PATIENTS; INFLUENZA VACCINE;

D O I：

10.1016/j.rdc.2016.09.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Patients with rheumatoid arthritis are highly vulnerable to infections because of abnormalities in their immune system, and because of immunosuppressive effects of their medications. Vaccinations in this population are complicated by disease-modifying antirheumatic drugs, which also modulate or suppress the immune system and potentially decrease the immunogenicity and efficacy of the vaccines. We review the available data regarding the impact of rheumatoid arthritis therapy on the immunogenicity of various common vaccines. We also review rheumatoid arthritis specific vaccination recommendations, live vaccine safety concerns, and current gaps in our understanding of these issues."

引用

页码：1 / +

页数：14

共 50 条

[31] Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis
Marguerie, L
Flipo, RM
Grardel, B
Beaurain, D
Duquesnoy, B
Delcambre, B
JOINT BONE SPINE, 2002, 69 (03) : 275 - 281
[32] Disease-modifying antirheumatic drugs and bone mass in rheumatoid arthritis
Di Munno, O
Delle Sedie, A
Rossini, A
Adamil, S
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2005, 23 (02) : 137 - 144
[33] Conventional disease-modifying antirheumatic drugs to treat rheumatoid arthritis
Rath, T.
Sander, O.
Rubbert, A.
DRUG DEVELOPMENT RESEARCH, 2011, 72 (08) : 657 - 663
[34] The effect of disease-modifying antirheumatic drugs on vaccine immunogenicity in adults
Day, Alvin Lee
Winthrop, Kevin L.
Curtis, Jeffrey R.
CLEVELAND CLINIC JOURNAL OF MEDICINE, 2020, 87 (11) : 695 - 703
[35] Clinically Important Drug Interactions with Disease-Modifying Antirheumatic Drugs
Cees J. Haagsma
Drugs & Aging, 1998, 13 : 281 - 289
[36] Clinically important drug interactions with disease-modifying antirheumatic drugs
Haagsma, CJ
DRUGS & AGING, 1998, 13 (04) : 281 - 289
[37] MANAGEMENT OF ADVERSE-EFFECTS OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
WIJNANDS, MJH
VANRIEL, PLCM
DRUG SAFETY, 1995, 13 (04) : 219 - 227
[38] PROTOCOL DEVELOPMENT FOR COMBINATION THERAPY WITH DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
PAULUS, HE
SEMINARS IN ARTHRITIS AND RHEUMATISM, 1993, 23 (02) : 19 - 25
[39] Safety of biological disease-modifying antirheumatic drugs in rheumatoid arthritis
Martinez-Mugica, Cristina
Salgueiro, Esther
FARMACIA HOSPITALARIA, 2022, 46 (01) : 15 - 20
[40] Tapering of disease-modifying antirheumatic drugs: an overview for daily practice
Maassen, Johanna Maria
van Ouwerkerk, Lotte
Aliaart, Cornelia Francina
LANCET RHEUMATOLOGY, 2021, 3 (09): : E659 - E670

← 1 2 3 4 5 →